Literature DB >> 11408375

Drug interaction between simvastatin and itraconazole in male and female rats.

M Ishigami1, K Kawabata, W Takasaki, T Ikeda, T Komai, K Ito, Y Sugiyama.   

Abstract

Taking into account the species and sex differences in drug interactions based on the inhibition of cytochrome P450 (P450)-mediated drug metabolism, we examined whether the interaction between simvastatin and itraconazole observed in humans could also occur in rats, the most commonly used animal species for pharmacokinetic studies. Itraconazole inhibited the in vitro metabolism of simvastatin in female rat liver microsomes, but not in male rat liver microsomes. Using anti-P450 antisera, the main P450 isozyme responsible for the metabolism of simvastatin was identified as CYP3A in female rats and CYP2C11 in male rats. Therefore, the sex difference in the inhibition of simvastatin metabolism by itraconazole seems to be caused by a difference in the P450 isozymes responsible for the metabolism of simvastatin in male and female rats and the different ability of itraconazole to inhibit CYP3A and CYP2C11. In addition, the effect of itraconazole on the pharmacokinetics of simvastatin in rats was also investigated. The area under the curve value of simvastatin was increased approximately 1.6-fold by the concomitant use of itraconazole (50 mg/kg) in female rats, whereas in male rats, itraconazole had no effect. In conclusion, it was found that the results obtained in male rats did not reflect the results in humans as far as the inhibition of simvastatin metabolism by itraconazole was concerned. The P450 isozymes involved in the metabolism of drugs should be taken into consideration when rats are used as a model animal for humans in the investigation of drug interactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408375

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Authors:  John D Clarke; Rhiannon N Hardwick; April D Lake; Mark J Canet; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2014-01-08       Impact factor: 4.030

2.  Effect of Myricetin on CYP2C8 Inhibition to Assess the Likelihood of Drug Interaction Using In Silico, In Vitro, and In Vivo Approaches.

Authors:  Shipra Bhatt; Diksha Manhas; Vinay Kumar; Abhishek Gour; Kuhu Sharma; Ashish Dogra; Probir Kumar Ojha; Utpal Nandi
Journal:  ACS Omega       Date:  2022-04-04

Review 3.  The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

Authors:  Yasmine Nivoix; Dominique Levêque; Raoul Herbrecht; Jean-Claude Koffel; Laurence Beretz; Genevieve Ubeaud-Sequier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis.

Authors:  Ziwei Li; Yuanfeng Lyu; Jiajia Zhao; Dan Li; Zhixiu Lin; Kenneth Kin Wah To; Xiaoyu Yan; Zhong Zuo
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

5.  Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats.

Authors:  Yeshwant Singh; Hari Narayan Kushwaha; Anamika Misra; Mahendra Kumar Hidau; Shio Kumar Singh
Journal:  Malar Res Treat       Date:  2014-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.